Biocon Biologics launches Nepexto in Australia
Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced it has launched Nepexto, a biosimilar to the reference product Enbrel (Etanercept), in Australia.
Nepexto will be promoted by Generic Health, the company's local partner and a provider of generic prescription, injectable and over-thecounter medicines, to expand access to patients in Australia.
Etanercept is a fusion-protein that inhibits tumor necrosis factor (TNF) and is used in the treatment of autoimmune diseases like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis.
Since receiving EU marketing authorization in 2020, Nepexto has earned broad adoption across Europe.
"Following the 2022 acquisition and vertical integration of the biosimilars business globally, Biocon Biologics is building on the solid foundation to strategically expand Nepexto into new markets worldwide and further strengthen our immunology offering," the company's spokesperson stated.
Nepexto is a registered trademark of Biosimilars New Co Limited, a Biocon Biologics Company.
Biocon Biologics is a global player in biosimilars and insulin production and has achieved many “firsts” in the industry including the first to receive approval of a trastuzumab in the United States, OGIVRI (Trastuzumab-dkst), as well as FULPHILA (Pegfilgrastim-jmdb) and the first U.S. approval of an interchangeable biosimilar for SEMGLEE (insulin glargine). Biocon Biologics has a comprehensive portfolio of in-market and in-development biosimilar products across multiple therapies, including seven approved biosimilars in the United States and six in Canada, with a development pipeline of 20 biosimilar assets, including insulins and monoclonal antibodies spanning multiple therapy areas.
